A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumors
NCT #
NCT05244551
Condition(s)
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
Molecular Target(s)
FGFR2/3
Drug Classification(s)
targeted
Agents(s)
ABSK061
Phase(s)
I
Mechanism of Action
ABSK061 inhibits FGFR2 and FGFR3. Inhibition of FGFR phosphorylation and signaling decreases cell viability. Selective inhibition avoids FGFR1 inhibition which potentially avoids side effects.
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from ABSK061
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Molecular Targeted Therapy, Trispecific Antibodies
ROR1
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.